Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Mar 14, 2013 10:02am

255 Views

Post# 21128808

RE: RE: RE: RE: RE: RE: RE: AGM Summary from trt o

Only to confirm the high stakes involved in this deal and how nice it would be to get more information....as far as the $4.00 purchase many investors won't play the roll the dice program...they invest in solid information. When we get to $4 and there is lots of volume, rest assured a much higher number will push itself up, week by week.

My concern is the recent loan increase that tells me we didn't get the licensing agreement DM taked about in Jan to retire then 25MM. On the other hand, maybe it's a delay.

bottom line...looking for more info as we move along into April.

Bullboard Posts

Who, why, and what of the great "Crypto Surge"